TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page 1/Line 1-2	Title
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Page 1-2/Line 3-35	Abstract
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page 2-3/Line 41-78	Introduction/Par 1-2
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page 3/ Line 76-78	Introduction/Par 3
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, ifapplicable.	Page 3/Line 84-86	Methods/Par 1
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Page 3/Line 84-85	Methods/Par 1
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Page 3/Line 84-87	Methods/Par 1
	5b	D;V	Describe eligibility criteria for participants.	Page 3-4/Line 89-96	Methods/Par 1
	5c	D;V	Give details of treatments received, if relevant.	Page 4/Line 96-97	Methods/Par 1
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page 5/Line 125-126	Methods/Par 2
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	Page 5/Line 133-134	Methods/Par 6
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Page 6/Line 159-160	Methods/Par 9
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	Page 5/Line 125	Methods/Par 5
Sample size	8	D;V	Explain how the study size was arrived at.	N/A	N/A

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Page 7/Line203	Methods/Par 14
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Page 6/Line 165-169	Methods/Par 9
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Page 6-7/Line 172-180	Methods/Par 9
	10c	V	For validation, describe how the predictions were calculated.	Page7/Line 185-195	Methods/Par10-13
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page8/Line 211-212	Statistical analysis/Par 14
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	N/A	N/A
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	N/A	N/A
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Page 7/Line 196-200	Methods/Par 13
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Page 4/Line 98	Results/Par 1
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Page 8-9/Line 239-242	Results/Par 1,Table1
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Page 8/Line 235	Results/Par 1
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	Page 8/Line 227-232	Results/Par 1
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	N/A	N/A
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Page 9/Line 250-260	Results/Par 3
	15b	D	Explain how to the use the prediction model.	Page 9/Line 247-248	Results/Par 2
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	Page 9/Line 261-264	Results/Par 4
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	N/A	N/A
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Page 11/Line 344-351	Discussion/Par 6

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Page 10-11/Line 288-301	Discussion/Par 1-2
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Page 11/Line 309-317	Discussion/Par 3
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	Page 11/Line 339-343	Discussion/Par 5
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Page 3/Line 89;Page 6/Line 161;Page 6/Line	Methods/Par 1,8,9; Results/Par 2,3,6
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	Page 13/Line 366	Acknowledgements/Par 1

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information:https://dx.doi.org/10.21037/qims-22-128
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.